程序性死亡受体1及程序性死亡受体配体1抑制剂在三阴性乳腺癌治疗中的研究进展  

Progress of programmed death-1/programmed death-ligand 1 inhibitors in treatment of triple-negative breast cancer

作　　者：李昕[1] 白海珍 山院飞[3] 薛江 郭钢[1] Li Xin;Bai Haizhen;Shan Yuanfei;Xue Jiang;Guo Gang(Department of Thyroid and Breast Surgery,the Affiliated Hospital of Inner Mongolian Medical University,Hohhot 010010,China;Department of Thyroid,Breast and Hernia Surgery,Inner Mongolia People's Hospital,Hohhot 010017,China;Department of Gastrointestinal Surgery,Tianjin First Central Hospital,Tianjin 300192,China;Department of Thyroid and Breast Surgery,Bayannur Hospital of Inner Mongolia Autonomous Region,Bayannur 015000,China)

机构地区：[1]内蒙古医科大学附属医院甲状腺乳腺外科,呼和浩特010010 [2]内蒙古自治区人民医院甲状腺乳腺疝气外科,呼和浩特010017 [3]天津市第一中心医院胃肠外科,300192 [4]内蒙古自治区巴彦淖尔市医院甲状腺乳腺外科,015000

出　　处：《肿瘤研究与临床》2021年第12期957-960,共4页Cancer Research and Clinic

摘　　要：乳腺癌是全球女性发病率最高的恶性肿瘤,其中三阴性乳腺癌(TNBC)免疫原性最高。因为没有明确的分子靶点,TNBC与其他乳腺癌亚型相比属于治疗难度更大、疾病预后更差的乳腺癌亚型。通过阻断程序性死亡受体1(PD-1)/程序性死亡受体配体1(PD-L1)的信号通路已经成为现今肿瘤治疗的研究热点。PD-1/PD-L1抑制剂为TNBC的治疗提供了新的治疗思路。文章综述了PD-1/PD-L1抑制剂单药或联合其他药物治疗TNBC的研究进展,为基础或临床研究提供理论基础。Breast cancer is the malignant tumor with the highest incidence among women in the worldwide.The triple-negative breast cancer(TNBC)has the strongest immunogenicity.Because of the lack of clear molecular targets,TNBC is a subtype of breast cancer with more difficulties in the treatment and poorer prognosis compared to other breast cancer subtypes.Blocking the programmed death-1(PD-1)/programmed death-ligand 1(PD-L1)signaling pathway has been a hot spot of research and treatment of tumors.PD-1/PD-L1 inhibitors provide new treatment options for TNBC.This article reviews the research progress of PD-1/PD-L1 inhibitors alone or in combination with other drugs in treatment of TNBC,intending to provide the theoretical basis for basic or clinical studies.

关 键 词：三阴性乳腺癌 程序性死亡受体1 程序性死亡受体配体1 

分 类 号：R737.9[医药卫生—肿瘤]